AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 211 min read$CLB

CLB Q3'26 Earnings: revenue estimate is 131.87M USD

Core Laboratories (CLB) will release Q3'26 earnings on October 28. Analysts estimate revenue of $131.87M and EPS of $0.16. Results will be announced after market close.

Original reporting
tradingview.com
Published Oct 21, 2026, 11:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 11:07 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
CLB Q3'26 Earnings: revenue estimate is 131.87M USD — source image
Source · tradingview.com
Decision brief

The 30-second read

$CLBNeutralMed
01

Why it matters

The earnings preview sets expectations for the upcoming release; investors will compare actual results to the $131.9M revenue and $0.16 EPS guidance.

02

Market read

The article introduces new guidance for a micro‑cap energy services company, offering a short‑term trading angle ahead of the earnings release.

03

What to watch

Potential hidden cost pressures or upcoming contract wins that are not reflected in the estimate.

Relevance 5/10Novelty 5/10Timing: pre‑market on Oct 28

Background

Core Laboratories is a provider of well‑testing and production‑optimization services for the oil and gas industry.

Company-level read

Ticker impact

$CLBNeutralMedium confidence
Context

Core Laboratories' Q3'26 revenue and EPS estimates are disclosed for the first time ahead of the earnings release.

Expected impact

potential modest move as investors price in the $131.9M revenue estimate and $0.16 EPS guidance

Evidence & confidence

Guidance is modest for a micro‑cap; no surprise factor, but first‑time disclosure creates a short‑term trading angle.

Market effects

Sector

Provides a data point for the oilfield services sector ahead of Q3 earnings season.

Regional

Limited to U.S. small‑cap investors tracking energy‑service stocks.

Global

Low; impact confined to Core Laboratories and its niche sector.

Counterpoint

What could challenge this read

If the guidance is viewed as too conservative, the stock could be oversold, presenting a buying opportunity.

Key entities

  • company
    Core Laboratories Inc.

    Oilfield services firm reporting Q3'26 earnings.

Read at source← All news

Related articles

JUL 29
$CLBMed

CORE LAB REPORTS SECOND QUARTER 2026 RESULTS

Core Laboratories (NYSE:CLB) reported Q2 2026 revenue of $124.6M, up 2% sequentially but down 4% year over year. Operating income was $9.2M, or $9.4M ex-items. GAAP EPS was $0.13, EPS ex-items $0.11. Free cash flow was $3.1M. The company repurchased 214,712 shares for $2.7M and announced a Q3 dividend.

prnewswire.com6 min
JUL 29
$CLBMed

CORE LAB REPORTS SECOND QUARTER 2026 RESULTS

Core Laboratories Inc. /DE/ (CLB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE CORE LAB REPORTS SECOND QUARTER 2026 RESULTS: • REVENUE OF $124.6 MILLION, UP 2% SEQUENTIALLY AND DOWN 4% YEAR-OVER-YEAR • OPERATING INCOME OF $9.2 MILLION; EX-ITEMS, $9.4 MILLION, UP 42% SEQUENTIALLY AND DOWN 36% YEAR-OVER-YEAR • GAAP EARNINGS

SEC EDGAR 8-K6 min
OCT 21
$NVSHighAI 8/10

Novartis (NVS) Grew Sales Again as Entresto Fell 50%, Can Remibrutinib Carry It?

Novartis (NVS) reported a 1% increase in Q2 net sales, with newer drugs like Kisqali and Scemblix growing, offsetting Entresto's 50% decline. The company won a second US approval for Rhapsido (remibrutinib) for chronic hives. Investors focus on upcoming MS data and Q3 results, as pipeline misses have raised pressure on growth prospects. NVS trades at 17.4x 2026 earnings, with consensus expecting a 1.65% EPS dip this year.

insidermonkey.com3 min